PositiveID Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
165.00
145.00
173.00
40.00
181.00
Total Accounts Receivable
-
-
764.00
307.00
75.00
Inventories
-
-
1,768.00
678.00
433.00
Other Current Assets
81.00
5.00
243.00
97.00
102.00
Total Current Assets
246.00
150.00
2,948.00
1,122.00
791.00
Net Property, Plant & Equipment
11.00
3.00
163.00
129.00
120.00
Intangible Assets
1,133.00
857.00
1,566.00
1,292.00
795.00
Other Assets
11.00
11.00
18.00
19.00
19.00
Total Assets
1,401.00
1,021.00
4,695.00
2,562.00
1,725.00
ST Debt & Current Portion LT Debt
1,156.00
4,355.00
1,837.00
4,608.00
6,175.00
Accounts Payable
498.00
127.00
248.00
394.00
295.00
Income Tax Payable
500.00
480.00
201.00
142.00
100.00
Other Current Liabilities
3,672.00
3,264.00
11,356.00
6,263.00
4,848.00
Total Current Liabilities
5,826.00
8,226.00
13,642.00
11,407.00
11,418.00
Long-Term Debt
-
1,241.00
2,711.00
18.00
8.00
Provision for Risks & Charges
-
-
184.00
-
-
Total Liabilities
5,826.00
9,467.00
16,537.00
11,425.00
11,426.00
Common Equity (Total)
4,913.00
8,446.00
11,843.00
8,863.00
9,603.00
Total Shareholders' Equity
4,425.00
8,446.00
11,842.00
8,863.00
9,603.00
Total Equity
4,425.00
8,446.00
11,842.00
8,863.00
9,701.00
Liabilities & Shareholders' Equity
1,401.00
1,021.00
4,695.00
2,562.00
1,725.00
Accumulated Minority Interest
-
-
-
-
98.00
Preferred Stock (Carrying Value)
488.00
-
1.00
-
-

About PositiveID

View Profile
Address
1690 South Congress Avenue
Delray Beach Florida 33445
United States
Employees -
Website http://www.psidcorp.com
Updated 07/08/2019
PositiveID Corp. engages in the development of molecular diagnostic systems for bio-threat detection and rapid medical testing. It operates through the following segments: Molecular Diagnostics, Medical Devices, Mobile Labs, and Corporate. The Molecular Diagnostics segment develops molecular diagnostic systems for rapid medical testing and bio-threat detection.